Article Details
Retrieved on: 2024-07-31 15:02:16
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets T1D with a disease-modifying ...
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here